Psyence Biomedical secures full control of psychedelic drug production with PsyLabs investment
Psyence Biomedical secures full control of psychedelic drug production with PsyLabs investment
Psyence Biomedical secures full control of psychedelic drug production with PsyLabs investment
Psyence Biomedical Ltd. has strengthened its position in the psychedelic pharmaceutical sector with a strategic investment in PsyLabs. The move secures full control over manufacturing, quality, and supply chain operations. This investment also eliminates corporate debt from the company's balance sheet, providing greater financial stability.
PsyLabs has already demonstrated its operational capabilities by exporting its first clinical trial product to Australia in 2026. The successful shipment highlights the readiness of its vertically integrated production model.
The investment in PsyLabs gives Psyence Biomedical direct ownership of a licensed, debt-free manufacturing operation. This includes GMP-compliant facilities capable of producing pharmaceutical-grade natural compounds at scale. The company now has access to essential source materials, including ibogaine and natural psilocybin, through PsyLabs' infrastructure.
Psyence Biomedical has also gained intellectual property protections and integrated analytical and chemistry laboratories. These enhancements reduce execution risks for its ongoing Phase IIb trial, which focuses on adjustment disorder in palliative care. By controlling the entire supply chain, the company improves regulatory compliance and commercialisation readiness.
While PsyLabs has proven its ability to export clinical trial products, no further updates on scalability or international supply chain expansion have been made public since 2026. The company's current focus remains on maintaining production efficiency and supporting Psyence Biomedical's research pipeline.
The investment solidifies Psyence Biomedical's long-term competitiveness in the psychedelic pharmaceutical market. With a debt-free, fully owned production operation, the company is better positioned to advance its clinical trials and commercial supply. The successful export to Australia further confirms the operational strength of its manufacturing model.